Use of the comet assay technique for quick and reliable prediction of in vitro response to chemotherapeutics in breast and colon cancer

被引：25

作者：

Apostolou, Panagiotis ^{[1
]}

Toloudi, Maria ^{[1
]}

Kourtidou, Eleni ^{[1
]}

Mimikakou, Georgia ^{[1
]}

Vlachou, Ioanna ^{[1
]}

Chatziioannou, Marina ^{[1
]}

Papasotiriou, Ioannis ^{[1
]}

机构：

[1] RGCC Ltd, Florina, Greece

来源：

JOURNAL OF BIOLOGICAL RESEARCH-THESSALONIKI | 2014年 / 21卷

关键词：

Comet assay; Personalized medicine; Breast cancer; Colon cancer; Cisplatin; Melphalan; Mechlorethamine; Doxorubicin; NEOADJUVANT CHEMOTHERAPY; COLORECTAL-CANCER; INDIVIDUAL CELLS; TUMOR RESPONSE; DNA-DAMAGE; THERAPY; AGENTS; VIVO; EXPRESSION;

D O I：

10.1186/2241-5793-21-14

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Background: Determination of response to chemotherapy is a major requirement of personalized medicine. Resistance, whether developed or native, critically affects a treatment's success. Single Cell Gel Electrophoresis - also known as a comet assay - is used to detect DNA damage at the level of individual eukaryotic cells. We assessed the use of comet assays in determining response to chemotherapeutic drugs that are widely used in breast and colon cancer. Results: We treated human breast and colon cancer cell lines with melphalan, cisplatin, mechlorethamine or doxorubicin, as monotherapies. Drug activities varied even in the same cancer types, further demonstrating the heterogeneity of different cancer types. Conclusion: The comet assay technique can provide reliable and quick results with minimum requirements and is applicable to a wide variety of drugs.

引用

页数：7

共 28 条

[11]

KARNOFSKY DA, 1950, ADV INTERNAL MED, V4, P1

[12] Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer [J].